Presentation is loading. Please wait.

Presentation is loading. Please wait.

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Published byAubrey Foster Modified over 5 years ago

Similar presentations

Presentation on theme: "Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction."— Presentation transcript:

1 Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) any stent thrombosis, (B) acute stent thrombosis (<24 h), and (C) subacute stent t... Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) any stent thrombosis, (B) acute stent thrombosis (<24 h), and (C) subacute stent thrombosis (≥24 h to 30 days). Mohamed Farag et al. Open Heart 2015;2:e000258 ©2015 by British Cardiovascular Society

Download ppt "Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction."

Similar presentations

HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.

HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.

Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:
Initial pharmacotherapy for ST-segment elevation myocardial infarction

Initial pharmacotherapy for ST-segment elevation myocardial infarction
Initial pharmacotherapy for ST-segment elevation myocardial infarction

Initial pharmacotherapy for ST-segment elevation myocardial infarction
by Nadine Martel, James Lee, and Philip S. Wells

by Nadine Martel, James Lee, and Philip S. Wells
Manuel Caceres, MD, Darryl S. Weiman, MD, JD 

Manuel Caceres, MD, Darryl S. Weiman, MD, JD 
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
ClinicalTrials.gov Identifier NCT

ClinicalTrials.gov Identifier NCT
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Figure 4 Observational studies on multiple treatment strategies

Figure 4 Observational studies on multiple treatment strategies
Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.
Prakash Harikrishnan et al. JACEP 2015;1:

Prakash Harikrishnan et al. JACEP 2015;1:
Tornado diagram of one-way deterministic sensitivity analysis.

Tornado diagram of one-way deterministic sensitivity analysis.
Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.
John A. Bittl et al. JACC 2016;68:

John A. Bittl et al. JACC 2016;68:

Similar presentations

Ads by Google